Susquehanna International Group, LLP Cerevel Therapeutics Holdings, Inc. Put Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 15, 2024	BUY	$38.96 - $42.75 $8.41 Million - $9.23 Million	215,800 Added 192.16%	328,100 $13.4 Million
Q1 2024 May 07, 2024	SELL	$40.88 - $43.27 $4.43 Million - $4.69 Million	-108,300 Reduced 49.09%	112,300 $4.75 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $3.37 Million - $7.06 Million	166,300 Added 306.26%	220,600 $9.35 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $3.03 Million - $4.78 Million	-149,800 Reduced 73.4%	54,300 $1.19 Million
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $497,119 - $735,904	-20,800 Reduced 9.25%	204,100 $6.49 Million
Q1 2023 May 16, 2023	BUY	$22.82 - $35.32 $3.85 Million - $5.95 Million	168,500 Added 298.76%	224,900 $5.49 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $1.93 Million - $2.43 Million	-76,000 Reduced 57.4%	56,400 $1.78 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $1.9 Million - $3.08 Million	74,400 Added 128.28%	132,400 $3.74 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.